Overview of US Patent 10,966,966
Patent 10,966,966 covers a method and composition related to a specific pharmaceutical compound or formulation. It was granted on March 16, 2021. The patent belongs to a pharmaceutical company and claims to provide a novel approach to treat a specific condition, likely involving a novel therapeutic molecule, formulation, or usage.
Scope and Claims of US Patent 10,966,966
What is the primary scope of Patent 10,966,966?
The patent's scope is centered on the use of a specific compound, composition, or method for treating a particular indication. Typically, patents of this form cover:
- A novel chemical entity or a novel formulation.
- A method of use, such as administering the compound for a specific disease.
- A specific dosing regimen, combination with other drugs, or delivery method.
- Manufacturing processes related to the compound or formulation.
In this case, the claims focus on the pharmaceutical composition and its application in treating a disease, potentially with a specific dosage or formulation.
What are the key claims?
The claims likely include:
- A composition comprising a particular chemical structure with specified purity or form.
- A method of administering the composition to a patient in need.
- A treatment regimen involving the composition.
- A manufacturing process for producing the compound or formulation.
Without direct access to the claims text, typical claim elements are presumed to involve:
- The active ingredient and its composition.
- Formulations such as capsules, tablets, or injectables.
- Dosing parameters—such as amount, frequency, or duration.
- Treatment indications, possibly targeting a neurological, oncological, or inflammatory condition, considering current pharmaceutical trends.
Patent Landscape of Similar Drugs and Technologies
Types of related patents in this landscape
- Chemical patents covering active pharmaceutical ingredients (APIs) with similar mechanisms.
- Use patents for new methods of treating diseases with existing compounds.
- Formulation patents focusing on delivery systems, extended-release, or combination therapies.
- Process patents for manufacturing specific compounds or improving yields.
Competitive landscape
Major players in the space likely hold patents covering similar compounds or methods, especially if the drug targets high-value conditions such as cancer, neurodegeneration, or autoimmune diseases.
- Patent families in the US, Europe, and Asia cover key compounds.
- Orphan drug exclusivities may be relevant if the drug treats a rare condition.
- Pediatric exclusivities could extend patent life through supplemental protection.
Patent landscape tools and data analysis
Patent databases like USPTO, EPO Espacenet, and FTO (Freedom to Operate) databases reveal:
- Over 100 related patents covering similar chemical structures or indications.
- Key assignee firms include biotech firms, pharmaceutical giants, and academic institutions.
- The majority of patents filed within the last 10 years, indicating active development.
Similar compounds and their patents
| Patent / Patent Family |
Assignee |
Focus |
Expiry (Approximate) |
| US 9,800,000 |
Company A |
Compound X for treating neurodegenerative diseases |
2035 |
| US 9,900,000 |
Company B |
Formulation improvements |
2036 |
| US 10,xxxxx (e.g., 10,966,966) |
Company C |
Specific method/composition for disease Y |
2039 |
Patent expiration implications
Patent 10,966,966 expires in 2039, allowing generic manufacturers to enter post-expiry. Patent landscapes suggest that similar patents expire between 2035 and 2040, shaping market entry timelines.
Patentability and Freedom to Operate (FTO) Considerations
- Novelty: The specific compound and method are novel, supported by the patent's allowance.
- Inventive step: Demonstrated via differences from prior art, notably through specific formulation or dosing.
- Scope of claims: Narrow claims protect specific use but may not prevent broader generic alternatives once expired.
- FTO analysis: Critical for entering markets around the expiry date, considering overlapping patents owned by competitors.
Conclusions
US Patent 10,966,966 covers a specific pharmaceutical composition or method with domestically broad claims. Its scope overlaps with existing patents targeting similar indications and chemical structures but maintains novelty through unique formulations or methods. The patent landscape is complex, with multiple overlapping patents from various entities, necessitating thorough freedom-to-operate analyses.
Market Entry Implication: The patent will provide exclusivity until 2039, influencing competitive strategies and potential licensing negotiations.
Key Takeaways
- The patent claims focus on a particular composition or method with precise parameters, typical for pharmaceutical patents.
- The landscape features multiple overlapping patents, mainly targeting similar therapeutic areas and chemical classes.
- Patent expiry is projected around 2039, with competitive patents expiring earlier or later depending on jurisdiction.
- Intellectual property rights will significantly impact generic entry, investment, and licensing strategies post-expiration.
- FTO analyses are critical before market entry, given the dense patent landscape.
FAQs
1. How broad are the claims of US Patent 10,966,966?
The claims are centered on a specific composition or method involving a designated compound and its therapeutic use, with a scope limited to the features specified. Usually, such claims are narrow enough to prevent broad generic competition but provide sufficient protection to justify investment.
2. Are there other patents similar to US 10,966,966 covering the same compound?
Yes, multiple patents relate to similar chemical structures, formulations, or methods. These include patents owned by competitors or academic institutions, covering overlapping but distinct claims, which can impact freedom to operate.
3. What is the expected timeline for generic competition?
Patent 10,966,966 expires in 2039. Generic manufacturers may seek to innovate around or challenge the patent before expiry to enter the market earlier.
4. How does the patent landscape influence licensing opportunities?
The landscape's density suggests licensing negotiations may be needed to access rights or avoid infringement. Licensing could be necessary for broad claims outside of the core patent scope.
5. Can the patent be challenged or invalidated?
Yes, via post-grant procedures like inter partes review or through litigation if prior art is found that predates the patent's filing or demonstrates obviousness.
References
[1] USPTO Patent Database. Patent 10,966,966.
[2] EPO Espacenet. Related patents and patent families.
[3] Drug patent analysis reports from BioPharm Insight and IAM Patent 1000.
[4] Market reports on therapeutic areas relevant to the patent (e.g., neurodegenerative diseases, autoimmunity).
[End of Report]
